MA26846A1 - Derives de 2,4-diaminopyrimidine utiles comme agents immunosuppresseurs. - Google Patents

Derives de 2,4-diaminopyrimidine utiles comme agents immunosuppresseurs.

Info

Publication number: MA26846A1
Authority: MA; Morocco
Prior art keywords: derivatives useful; immunosuppressant agents; diaminopyrimidine derivatives; diaminopyrimidine; immunosuppressant
Prior art date: 1999-11-30

Application number

MA26655A

Other languages

English (en)

Inventor

Andrew Blumenkopf Todd

Jan Roskamp Eric

Elliott Mueller Eileen

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-30

Filing date

2002-05-28

Publication date

2004-12-20

2002-05-28 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-12-20 Publication of MA26846A1 publication Critical patent/MA26846A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

MA26655A 1999-11-30 2002-05-28 Derives de 2,4-diaminopyrimidine utiles comme agents immunosuppresseurs. MA26846A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US16822499P	1999-11-30	1999-11-30

Publications (1)

Publication Number	Publication Date
MA26846A1 true MA26846A1 (fr)	2004-12-20

Family

ID=22610621

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26655A MA26846A1 (fr)	1999-11-30	2002-05-28	Derives de 2,4-diaminopyrimidine utiles comme agents immunosuppresseurs.

Country Status (33)

Country	Link
EP (1)	EP1242403B1 (fr)
JP (1)	JP3955468B2 (fr)
KR (1)	KR20020059826A (fr)
CN (1)	CN1402720A (fr)
AP (1)	AP2002002530A0 (fr)
AT (1)	ATE315036T1 (fr)
AU (1)	AU1047601A (fr)
BG (1)	BG106695A (fr)
BR (1)	BR0015995A (fr)
CA (1)	CA2392971C (fr)
CO (1)	CO5261519A1 (fr)
CZ (1)	CZ20021703A3 (fr)
DE (1)	DE60025385T2 (fr)
EA (1)	EA200200411A1 (fr)
EE (1)	EE200200275A (fr)
ES (1)	ES2253266T3 (fr)
GT (1)	GT200000200A (fr)
HN (1)	HN2000000264A (fr)
HU (1)	HUP0203300A3 (fr)
IL (1)	IL149103A0 (fr)
IS (1)	IS6339A (fr)
MA (1)	MA26846A1 (fr)
MX (1)	MXPA02005350A (fr)
NO (1)	NO20022557L (fr)
OA (1)	OA12097A (fr)
PA (1)	PA8506801A1 (fr)
PE (1)	PE20010900A1 (fr)
PL (1)	PL355946A1 (fr)
SV (1)	SV2002000231A (fr)
TN (1)	TNSN00232A1 (fr)
TR (1)	TR200201431T2 (fr)
UY (1)	UY26455A1 (fr)
WO (1)	WO2001040215A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030004174A9 (en) *	2000-02-17	2003-01-02	Armistead David M.	Kinase inhibitors
SK2002003A3 (en) *	2000-08-31	2004-04-06	Pfizer Prod Inc	Pyrazole derivatives and their use as protein kinase inhibitors
US7473691B2 (en)	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
ATE346064T1 (de)	2000-09-15	2006-12-15	Vertex Pharma	Pyrazolverbindungen als protein-kinasehemmer
US6660731B2 (en)	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
ATE354573T1 (de)	2000-12-21	2007-03-15	Vertex Pharma	ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
WO2003030909A1 (fr) *	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
MY141867A (en)	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
CN1319968C (zh)	2002-08-02	2007-06-06	沃泰克斯药物股份有限公司	用作gsk－3的抑制剂的吡唑组合物
US20040204458A1 (en)	2002-08-16	2004-10-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) *	2002-08-16	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
BRPI0506839A (pt) *	2004-01-16	2007-06-12	Novartis Ag	composições e métodos para induzir a cardiomiogênese
JP2008515980A (ja) *	2004-10-12	2008-05-15	デコードジェネティクスイーエイチエフ	閉塞性動脈疾患のためのアリールスルホンアミドぺリ置換二環式化合物
US20060161001A1 (en) *	2004-12-20	2006-07-20	Amgen Inc.	Substituted heterocyclic compounds and methods of use
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP5249770B2 (ja)	2005-11-03	2013-07-31	バーテックスファーマシューティカルズインコーポレイテッド	キナーゼインヒビターとして有用なアミノピリジン
ATE479434T1 (de)	2006-02-14	2010-09-15	Vertex Pharma	Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
MX2008011661A (es) *	2006-03-16	2008-09-22	Novartis Ag	Compuestos organicos heterociclicos para el tratamiento de melanoma en particular.
EP2146722A4 (fr)	2007-05-10	2011-08-03	Amr Technology Inc	Tétrahydrobenzo-l,4-diazépines substituées par un aryle ou un hétéroaryle et utilisation desdites dans le blocage de la réassimilation de la norépinéphrine, de la dopamine et de la sérotonine
CA2710182C (fr)	2007-10-16	2012-08-14	Daiichi Sankyo Company, Limited	Compose de pyrimidylindoline
KR20120096474A (ko)	2009-09-25	2012-08-30	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
JP2013505927A (ja)	2009-09-25	2013-02-21	バーテックスファーマシューティカルズインコーポレイテッド	プロテインキナーゼ阻害剤として有用なピリミジン誘導体の調製方法
TWI513694B (zh) *	2010-05-11	2015-12-21	Amgen Inc	抑制間變性淋巴瘤激酶的嘧啶化合物
KR101708761B1 (ko) *	2012-04-13	2017-02-21	주식회사 머쉬메드	퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물
US10125144B2 (en)	2013-10-07	2018-11-13	Kadmon Corporation, Llc	Rho kinase inhibitors
JP2020525525A (ja)	2017-06-30	2020-08-27	ベイジンタイドファーマシューティカルカンパニーリミテッドＢｅｉｊｉｎｇＴｉｄｅＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
WO2019000683A1 (fr)	2017-06-30	2019-01-03	北京泰德制药股份有限公司	Inhibiteur de protéine kinase associée à rho, composition pharmaceutique contenant celui-ci, son procédé de préparation et ses applications
ES2969536T3 (es) *	2017-06-30	2024-05-21	Beijing Tide Pharmaceutical Co Ltd	Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
EP0837063A1 (fr) *	1996-10-17	1998-04-22	Pfizer Inc.	Dérivés de 4-aminoquinazoline
GB9905075D0 (en) *	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds

2000
- 2000-11-09 EA EA200200411A patent/EA200200411A1/ru unknown
- 2000-11-09 CN CN00816506A patent/CN1402720A/zh active Pending
- 2000-11-09 AU AU10476/01A patent/AU1047601A/en not_active Abandoned
- 2000-11-09 OA OA1200200156A patent/OA12097A/en unknown
- 2000-11-09 PL PL00355946A patent/PL355946A1/xx not_active Application Discontinuation
- 2000-11-09 DE DE60025385T patent/DE60025385T2/de not_active Expired - Lifetime
- 2000-11-09 IL IL14910300A patent/IL149103A0/xx unknown
- 2000-11-09 AP APAP/P/2002/002530A patent/AP2002002530A0/en unknown
- 2000-11-09 EE EEP200200275A patent/EE200200275A/xx unknown
- 2000-11-09 MX MXPA02005350A patent/MXPA02005350A/es active IP Right Grant
- 2000-11-09 CA CA002392971A patent/CA2392971C/fr not_active Expired - Fee Related
- 2000-11-09 ES ES00971650T patent/ES2253266T3/es not_active Expired - Lifetime
- 2000-11-09 KR KR1020027006941A patent/KR20020059826A/ko not_active Ceased
- 2000-11-09 BR BR0015995-6A patent/BR0015995A/pt not_active Application Discontinuation
- 2000-11-09 JP JP2001541899A patent/JP3955468B2/ja not_active Expired - Fee Related
- 2000-11-09 AT AT00971650T patent/ATE315036T1/de not_active IP Right Cessation
- 2000-11-09 CZ CZ20021703A patent/CZ20021703A3/cs unknown
- 2000-11-09 EP EP00971650A patent/EP1242403B1/fr not_active Expired - Lifetime
- 2000-11-09 TR TR2002/01431T patent/TR200201431T2/xx unknown
- 2000-11-09 WO PCT/IB2000/001628 patent/WO2001040215A1/fr not_active Ceased
- 2000-11-09 HU HU0203300A patent/HUP0203300A3/hu unknown
- 2000-11-22 PA PA20008506801A patent/PA8506801A1/es unknown
- 2000-11-23 HN HN2000000264A patent/HN2000000264A/es unknown
- 2000-11-28 PE PE2000001268A patent/PE20010900A1/es not_active Application Discontinuation
- 2000-11-28 UY UY26455A patent/UY26455A1/es not_active Application Discontinuation
- 2000-11-29 GT GT200000200A patent/GT200000200A/es unknown
- 2000-11-29 SV SV2000000231A patent/SV2002000231A/es unknown
- 2000-11-29 TN TNTNSN00232A patent/TNSN00232A1/fr unknown
- 2000-11-30 CO CO00091745A patent/CO5261519A1/es unknown
2002
- 2002-04-12 IS IS6339A patent/IS6339A/is unknown
- 2002-05-13 BG BG106695A patent/BG106695A/bg unknown
- 2002-05-28 MA MA26655A patent/MA26846A1/fr unknown
- 2002-05-29 NO NO20022557A patent/NO20022557L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0203300A2 (hu)	2003-02-28
HN2000000264A (es)	2001-05-21
KR20020059826A (ko)	2002-07-13
AU1047601A (en)	2001-06-12
PL355946A1 (en)	2004-05-31
EE200200275A (et)	2003-10-15
EP1242403B1 (fr)	2006-01-04
EP1242403A1 (fr)	2002-09-25
JP3955468B2 (ja)	2007-08-08
CA2392971C (fr)	2008-10-07
MXPA02005350A (es)	2002-12-11
TNSN00232A1 (fr)	2005-11-10
NO20022557D0 (no)	2002-05-29
NO20022557L (no)	2002-05-29
CZ20021703A3 (cs)	2003-06-18
TR200201431T2 (tr)	2002-09-23
BR0015995A (pt)	2002-08-06
CA2392971A1 (fr)	2001-06-07
CN1402720A (zh)	2003-03-12
DE60025385D1 (de)	2006-03-30
GT200000200A (es)	2002-05-23
WO2001040215A1 (fr)	2001-06-07
UY26455A1 (es)	2001-07-31
BG106695A (bg)	2002-12-29
SV2002000231A (es)	2002-07-16
PE20010900A1 (es)	2001-09-08
IS6339A (is)	2002-04-12
OA12097A (en)	2006-05-04
PA8506801A1 (es)	2002-04-25
AP2002002530A0 (en)	2002-06-30
IL149103A0 (en)	2002-11-10
DE60025385T2 (de)	2006-08-24
EA200200411A1 (ru)	2002-10-31
HUP0203300A3 (en)	2003-10-28
JP2003515602A (ja)	2003-05-07
ES2253266T3 (es)	2006-06-01
CO5261519A1 (es)	2003-03-31
ATE315036T1 (de)	2006-02-15

Publication	Publication Date	Title
MA26846A1 (fr)	2004-12-20	Derives de 2,4-diaminopyrimidine utiles comme agents immunosuppresseurs.
DZ3327A1 (fr)	2001-06-07	Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA26831A1 (fr)	2004-12-20	Derives de benzodiazepine."
PT1177185E (pt)	2005-08-31	Derivados de 4, 5, 6, 7-tetra-hidroindazole como agentes antitumorais
MA26520A1 (fr)	2004-12-20	Derives de la 5h-thiazolo (3,2-a) pyrimidine.
MA26385A1 (fr)	2004-11-01	Derives de 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate
MA26832A1 (fr)	2004-12-20	Derives de benzodiazepine.
DZ3159A1 (fr)	2001-04-19	Derives de purine.
MA26825A1 (fr)	2004-12-20	Derives de pyrazolo [4,3-d] pyrimidine
IT1313574B1 (it)	2002-09-09	Rete correttiva per tessuti corporei.
MA26824A1 (fr)	2004-12-20	5-(2-substitué-5-hétérocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidine-7-ones servant d'inhibiteurs de phosphodiestérase.
MA26851A1 (fr)	2004-12-20	Derives de pyrrolo [2,3-d] pyrimidine
DE122011100004I1 (de)	2011-09-08	Triazolo[4,5-D]pyrimidin-derivate.
TR200000520A3 (tr)	2001-06-21	4-Fenil-piridin türevleri.
MA26794A1 (fr)	2004-12-20	Derives de 5-phenyl-pyrimidine.
MA26504A1 (fr)	2004-12-20	Derives benzimidazole.
FR14C0044I2 (fr)	2015-02-20	Derives de 3-(2-oxo- 1,3']bipyrrolidinyl-3-ylidenemethyl)-cephemes
MA26503A1 (fr)	2004-12-20	Derives de 5'-desoxy-cytidine.
PT901488E (pt)	2003-03-31	Derivados de 2,4-diaminopirimidina
DZ3036A1 (fr)	2004-03-27	Dérivés de monofluoroalkyles.
MA26793A1 (fr)	2004-12-20	Derives de 4-phenyl-pyrimidine.
NO20003825L (no)	2000-07-26	1,3,4 - oxadiazolonderivater
DE60025958D1 (de)	2006-04-20	14,15-beta-methylen substituierte androgene
DE69906149D1 (de)	2003-04-24	4,5-azolo-oxindole
PT1129079E (pt)	2006-05-31	Derivados de triazina 2,4-dissubstituidos